期刊
CYTOKINE & GROWTH FACTOR REVIEWS
卷 19, 期 3-4, 页码 285-294出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.cytogfr.2008.04.004
关键词
tumor; metastasis; immunotherapy; TNF superfamily; gene therapy; T cells
资金
- NATIONAL CANCER INSTITUTE [R01CA115540] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI062026] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058897] Funding Source: NIH RePORTER
- NCI NIH HHS [R01 CA115540-03, R01 CA115540-02, R01 CA115540] Funding Source: Medline
- NIAID NIH HHS [R01 AI062026-07, R01 AI062026-09, R01 AI062026, R01 AI062026-08] Funding Source: Medline
- NIDDK NIH HHS [R01 DK058897-08, R01 DK058897-07, R01 DK058897] Funding Source: Medline
Metastatic diseases cause the majority of morbidity and mortality of cancer patients. Established tumors form both physical and immunological barriers to limit immune detection and destruction. Current immunotherapy of vaccination and adoptive transfer shows limited effect at least in part due to the existing barriers in the tumors and depending on the knowledge of tumor antigens. Tumor necrosis factor (TNF) superfamily (TNFSF) member 14 (TNFSF14) LIGHT interacts with stromal cells, dendritic cells (DCs), NK cells, naive and activated T cells and tumor cells inside the tumor tissues via its two functional receptors, HVEM and lymphotoxin beta receptor (LT beta R). Targeting tumor tissues with LIGHT leads to augmentation of priming, recruitment, and retention of effector cells at tumor sites, directly or indirectly, to induce strong anti-tumor immunity to inhibit the growth of primary tumors as well as eradicate metastases. Intratumor treatment would break tumor barriers and allow strong immunity against various tumors without defining tumor antigens. This review summarizes recent findings to support that LIGHT is a promising candidate for an effective cancer immunotherapy. (c) 2008 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据